Abstract | BACKGROUND: The clinical effects of antidepressant combinations vs. monotherapy as initial treatment for major depression with melancholic features (MDD-MF) are unknown. METHODS: Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial. Secondary data analyses were conducted to compare demographic and clinical characteristics, and contrast clinical responses according to drug treatment, in patients with MDD-MF (n=124) and non-melancholic MDD (n=481). RESULTS: While numerically lower, remission rates in MDD-MF did not differ significantly from those with non-melancholic MDD either at 12 (33.1% vs. 41.0%, aOR 1.16, p=0.58) or 28 (39.5% vs. 46.8%, aOR=1.02, p=0.93) weeks of treatment. Remission rates did not differ significantly between combination and monotherapy groups in either MDD-MF or non-melancholic MDD patients at either time point. Similar conclusions were reached for response rates, premature study discontinuation, and self-rated depression symptom severity. LIMITATIONS: This is a secondary analysis of data from the CO-MED trial, which was not designed to address differential treatment response in melancholic and non-melancholic MDD. CONCLUSIONS: We found no evidence of differential remission or response rates to antidepressant combination or monotherapy between melancholic/non-melancholic MDD patients, or according to antidepressant treatment group, after 12 and 28 weeks. Melancholic features may not be a valid predictor of more favorable response to antidepressant combination therapy as initial treatment.
|
Authors | William V Bobo, Helen Chen, Madhukar H Trivedi, Jonathan W Stewart, Andrew A Nierenberg, Maurizio Fava, Benji T Kurian, Diane Warden, David W Morris, James F Luther, Mustafa M Husain, Ian A Cook, Ira M Lesser, Susan G Kornstein, Stephen R Wisniewski, A John Rush, Richard C Shelton |
Journal | Journal of affective disorders
(J Affect Disord)
Vol. 133
Issue 3
Pg. 467-76
(Oct 2011)
ISSN: 1573-2517 [Electronic] Netherlands |
PMID | 21601287
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2011 Elsevier B.V. All rights reserved. |
Chemical References |
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Cyclohexanols
- Serotonin Uptake Inhibitors
- Bupropion
- Citalopram
- Venlafaxine Hydrochloride
|
Topics |
- Adult
- Aged
- Antidepressive Agents
(adverse effects, therapeutic use)
- Antidepressive Agents, Second-Generation
(therapeutic use)
- Bupropion
(therapeutic use)
- Citalopram
(adverse effects, therapeutic use)
- Cyclohexanols
(therapeutic use)
- Depression
- Depressive Disorder
(chemically induced, diagnosis, drug therapy)
- Depressive Disorder, Major
(chemically induced, diagnosis, drug therapy)
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- Outpatients
- Selective Serotonin Reuptake Inhibitors
(adverse effects, therapeutic use)
- Single-Blind Method
- Treatment Outcome
- Venlafaxine Hydrochloride
|